KS Kewaunee Scientific CORP Stock: price and management transactions · United States · SEC (Form 4)Follow the Kewaunee Scientific CORP stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Kewaunee Scientific CORP has logged 45 public disclosures. Market capitalisation: €104m. The latest transaction was filed on 1 July 2022 (Levée d'options). Among the most active insiders: HULL THOMAS DAVID III. Every trade is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,731 of 29,065 companies
FCF yld 14%
Earn yld 9.2%
EV/EBITDA 5.6x
ROE 15%
Gross mgn 29%
Net mgn 3.4%
Debt/EBITDA 1.3x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2022
All Executives45 Thresholds0 Prospectus0 Other0
Declarations 45 total
◇ VP-Sales & Marketing-Americas · Executives · 30 Jun 2022
1,634 shares 0Common Stock SEC:0001747001-22-000006:0
◇ President, CEO · Executives · 30 Jun 2022
5,096 shares 0Common Stock SEC:0001657070-22-000005:0
◇ VP-Information Technology · Executives · 30 Jun 2022
1,638 shares 0Common Stock SEC:0001795887-22-000005:0
◇ VP of Manufacturing Operations · Executives · 30 Jun 2022
1,689 shares 0Common Stock SEC:0001814145-22-000003:0
◆ Chief Financial Officer · Executives · 29 Jun 2022
3,000 shares 0Common Stock SEC:0001775052-22-000005:0
◇ VP - Human Resources · Executives · 30 Jun 2022
1,504 shares 0Common Stock SEC:0001467437-22-000006:0
◇ Chief Financial Officer · Executives · 21 Jun 2022
3,400 shares 0Common Stock SEC:0001775052-22-000002:0
◇ VP-Sales & Marketing-Americas · Executives · 21 Jun 2022
2,243 shares 0Common Stock SEC:0001747001-22-000003:0
◇ VP - Human Resources · Executives · 21 Jun 2022
2,065 shares 0Common Stock SEC:0001467437-22-000003:0
◇ President, CEO · Executives · 21 Jun 2022
7,138 shares 0Common Stock SEC:0001657070-22-000002:0
◇ VP-Information Technology · Executives · 21 Jun 2022
2,049 shares 0Common Stock SEC:0001795887-22-000002:0
◆ Director · Executives · 2 May 2022
2,911 shares 0Common Stock SEC:0001240461-22-000004:0
◇ VP - Human Resources · Executives · 20 Aug 2021
1,500 shares @ US$8.59 100.0% of flow Common Stock SEC:0001467437-21-000010:0
▼ Director · Executives · 1 Jul 2021
100 shares @ US$14.37 100.0% of flow Common Stock SEC:0001775052-21-000009:0
◇ VP-Sales & Marketing-Americas · Executives · 16 Jul 2021
197 shares 0Common Stock SEC:0001747001-21-000008:0
◆ VP-Information Technology · Executives · 8 Jul 2021
884 shares 0Common Stock SEC:0001795887-21-000006:0
◆ VP-Sales & Marketing-Americas · Executives · 8 Jul 2021
881 shares 0Common Stock SEC:0001747001-21-000006:0
◆ Chief Financial Officer · Executives · 8 Jul 2021
1,309 shares 0Common Stock SEC:0001775052-21-000008:0
◆ VP of Manufacturing Operations · Executives · 8 Jul 2021
911 shares 0Common Stock SEC:0001814145-21-000004:0
◆ President, CEO · Executives · 8 Jul 2021
2,749 shares 0Common Stock SEC:0001657070-21-000010:0
◆ VP-Construction/Cust. Servs. · Executives · 8 Jul 2021
589 shares 0Common Stock SEC:0001751189-21-000008:0
◆ VP - Human Resources · Executives · 8 Jul 2021
811 shares 0Common Stock SEC:0001467437-21-000008:0
◆ VP - Global Prod Development · Executives · 8 Jul 2021
645 shares 0Common Stock SEC:0001262059-21-000008:0
◇ VP-Construction/Cust. Servs. · Executives · 28 Jun 2021
160 shares 0Common Stock SEC:0001751189-21-000006:0
◇ VP - Global Prod Development · Executives · 28 Jun 2021
181 shares 0Common Stock SEC:0001262059-21-000006:0
25 of 45 declarations
Load more (20 remaining) 关于 Kewaunee Scientific CORP Kewaunee Scientific Corp /DE/ (NASDAQ: KEQU, United States) 是一家利基市场供应商,提供实验室、医疗保健和技术家具及基础设施解决方案。公司成立于 1906 年,在专业市场中拥有悠久的运营历史,在该市场中,执行质量、合规性以及交付复杂项目的能力与产品设计同样重要。其公司总部位于北卡罗来纳州斯泰茨维尔,并在美国、印度、沙特阿拉伯和新加坡设有商业运营。Kewaunee 还在斯泰茨维尔和班加罗尔设有制造工厂,使其能够满足国内和国际需求。([kewaunee.com](https://kewaunee.com/wp-content/uploads/2025/07/FY25-Annual-Report-Proof-FINAL.pdf))
公司的核心业务集中在实验室装修和技术家具。其产品范围包括钢制和木制柜体、通风橱、适应性模块化系统、可移动工作站、独立工作台、环氧树脂工作台面和水槽,以及科学环境的相关基础设施。2024 年 11 月,Kewaunee 通过收购 NuAire 扩大了其产品组合,增加了生物安全柜、CO2 培养箱、超低温冰箱和其他必要的实验室产品。NuAire 扩大了集团的产品范围,并增强了其向研究、医疗保健和生命科学客户销售更全面解决方案的能力。Kewaunee 还提供设施设计、详细工程、项目管理和调试服务,尤其是在其国际业务中。([kewaunee.com](https://kewaunee.com/wp-content/uploads/2025/07/FY25-Annual-Report-Proof-FINAL.pdf))
从竞争角度来看,Kewaunee 在一个高度分散但要求严格的行业中运营,该行业与实验室、医院、大学、制药和工业资本支出相关。其差异化因素包括制造技术、基于经销商的市场进入模式、国际影响力以及 NuAire 收购后更广泛的产品组合。公司不再仅仅在家具方面竞争,而是越来越多地将自己定位为设备齐全的实验室空间的解决方案提供商,这可以提高客户粘性和项目范围。([kewaunee.com](https://kewaunee.com/wp-content/uploads/2025/07/FY25-Annual-Report-Proof-FINAL.pdf))
最近的发展与投资者相关。公司 2026 财年的披露显示出强劲的运营势头,包括第二季度销售额同比强劲增长和第三季度税前利润增加。管理层还指出健康的订单积压和 NuAire 的贡献,同时提醒季度业绩可能因项目时间和供应链中断而保持不均衡。对于法语投资者而言,KEQU 最好被视为一家在美国纳斯达克上市的专业工业医疗保健/生命科学供应商,其历史、国际足迹和产品广度支持其利基市场地位。([sec.gov](https://www.sec.gov/Archives/edgar/data/55529/000005552925000051/prfy26q2earningsrelease.htm?utm_source=openai))